AIRLUKAST TABLETS 10 mg

Šalis: Malaizija

kalba: anglų

Šaltinis: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Veiklioji medžiaga:

MONTELUKAST SODIUM

Prieinama:

RANBAXY (MALAYSIA) SDN. BHD.

INN (Tarptautinis Pavadinimas):

MONTELUKAST SODIUM

Vienetai pakuotėje:

3x10tablet Tablets; 6x10tablet Tablets; 10x10tablet Tablets

Pagaminta:

RANBAXY (MALAYSIA) SDN. BHD.

Pakuotės lapelis

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
AIRLUKAST TABLETS
MONTELUKAST SODIUM TABLETS( 10 MG)_ _
Page 1
WHAT IS IN THIS LEAFLET
1.
What AIRLUKAST TABLETS
is
used for
2.
How
AIRLUKAST
TABLETS
works
3.
Before
you
use
AIRLUKAST
TABLETS
4.
How
to
use
AIRLUKAST
TABLETS
5.
While you are using it
6.
Side Effects
7.
Storage
and
disposal
of
AIRLUKAST TABLETS
8.
Product description
9.
Manufacturer
and
Product
registration holder
10.
Date of revision
All medicines have risks and benefits.
Your doctor has weighed the risks of you
taking
AIRLUKAST TABLETS
against
the benefits it is expected to have for you.
If you have any concerns about taking this
medicine, ask your doctor or pharmacist.
Keep this leaflet with the medicine. You
may need to read it again.
WHAT AIRLUKAST TABLETS IS USED
FOR
AIRLUKAST TABLETS
is used for

prevention and treatment of asthma in
adults

relief
of
day
time
and
night
time
symptoms of seasonal allergic rhinitis
in adults.
Symptoms of asthma include coughing,
wheezing
and
chest
tightness.
Not
all
people with
asthma wheeze. For some,
coughing may be the only symptom of
asthma. Symptoms often occur during the
night or after exercise.
Seasonal allergic rhinitis (also known as
hay fever) is an allergic response often
caused by airborne pollens from trees,
grasses,
and
weeds.
The
daytime
and
nighttime symptoms of seasonal allergic
rhinitis
typically
may
include:
stuffy,
runny,
itchy
nose;
sneezing;
watery,
swollen, red, itchy eyes.
HOW AIRLUKAST TABLETS WORKS
AIRLUKAST
TABLETS
contain
the
active ingredient, montelukast which is a
leukotriene receptor antagonist that blocks
substances called leukotrienes.
Leukotrienes
cause
narrowing
and
swelling of airways in your lungs. By
blocking
leukotrienes,
montelukast
improves asthma symptoms, helps control
asthma
and
improves
seasonal
allergic
rhinitis symptoms.
ASK
YOUR
DOCTOR
IF
YOU
HAVE
ANY
QUESTIONS
ABOUT
WHY
AIRLUKAST
TABLETS HAS BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed it for
another reason.
This medicine is available only wit

Prekės savybės

pg. 1
_For the use only of a Registered Medical Practitioner _
PRESCRIBING INFORMATION
AIRLUKAST TABLETS
(Montelukast Sodium Tablets 10 mg)
COMPOSITION
Each film coated tablet contains:
Montelukast Sodium equivalent to
Montelukast ………………………10 mg
PRODUCT DESCRIPTION
Beige to light yellow coloured, rounded square, film-coated tablets,
engraved with ‘10’ on one side and
scored on the other side.
DESCRIPTION
AIRLUKAST contain montelukast sodium, which is a selective and orally
active leukotriene receptor
antagonist that inhibits the cysteinyl leukotriene CysLT
1
receptor. It is chemically described as [R-(E)]-
1-[[[1-[3-[2-(7-chloro-2-quinolinyl)
ethenyl]
phenyl]-3-[2-(1-hydroxy-1-methyl
ethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid, monosodium
salt. Its empirical formula is
C
35
H
35
ClNNaO
3
S, and its molecular weight is 608.18. The structural formula is:
MONTELUKAST SODIUM
PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES
PHARMACODYNAMICS
The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of
arachidonic acid metabolism and are
released from various cells, including mast cells and eosinophils.
These eicosanoids bind to cysteinyl
leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is
found in the human airway
(including airway smooth muscle cells and airway macrophages) and on
other pro-inflammatory cells
pg. 2
(including eosinophils and certain myeloid stem cells). CysL Ts have
been correlated with the
pathophysiology of asthma and allergic rhinitis. In asthma,
leukotriene-mediated effects include airway
edema, smooth muscle contraction, and altered cellular activity
associated with the inflammatory
process. In allergic rhinitis, CysL Ts are released from the nasal
mucosa after allergen exposure during
both early-and late-phase reactions and are associated with symptoms
of allergic rhinitis.
Montelukast is an orally active compound that binds with high affinity
and selectivity to the CysLT1
receptor (in preference to other pharmacologically important airway
recep